Patent details

EP2993180 Title: NOVEL JNK INHIBITOR MOLECULES

Basic Information

Publication number:
EP2993180
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP150022119
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
NOVEL JNK INHIBITOR MOLECULES
French Title of Invention:
NOUVELLES MOLÉCULES D'INHIBITEUR JNK
German Title of Invention:
NEUARTIGE JNK-HEMMERMOLEKÜLE
SPC Number:

Dates

Filing date:
21/06/2011
Grant date:
15/01/2020
EP Publication Date:
09/03/2016
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
15/01/2020
EP B1 Publication Date:
15/01/2020
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
21/06/2020
Expiration date:
21/06/2031
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
08/01/2020
 
 

Name:
Xigen Inflammation Ltd.
Address:
Arch. Makariou III 195 Neocleous House, 3030 Limassol, Cyprus (CY)

Inventor

Name:
Bonny, Christophe
Address:
Switzerland (CH)

Priority

Priority Number:
PCT/EP2010/003729
Priority Date:
21/06/2010
Priority Country:
World Intellectual Property Office (WIPO) (WO)

Classification

IPC classification:
C07K 7/06; C07K 14/47; G01N 33/53;

Publication

European Patent Bulletin

Issue number:
202003
Publication date:
15/01/2020
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages